Predicting cancer patient response to drugs that block DNA repair
Testing for genetic biomarkers can predict which cancer patients are likely to benefit from DNA…
Browsing: PARP inhibitor
Existing cancer drugs have potential to benefit thousands more patients
New research, published in Nature Genetics, shows that more people may benefit from PARP inhibitor drugs,…
Oestrogen and PARP inhibitor combination for advanced ER+ breast cancer shows promise in preclinical models
Advanced oestrogen receptor-positive (ER+) breast cancer can be especially difficult to treat. A new study…
HRD detection predicts sensitivity to platinum-based chemotherapy for ovarian cancer patients in China
Homologous Recombination Deficiency (HRD) is a biomarker that predicts ovarian cancer treatment with PARP inhibitors…
PARP inhibitor treatment potential for some prostate cancer brain metastases
Around 6,600 men are diagnosed with prostate cancer in Switzerland every year. It is the…
New BRCA-targeting drug could offer hope in treating advanced prostate cancer
Talazoparib, a new precision drug, can keep cancer in check in some men with advanced prostate…
ASCO 2021: PARP inhibitor significantly improved disease-free survival in patients with high-risk early-stage HER2-negative breast cancer with BRCA 1/2 mutations
The addition of 1 year of the PARP inhibitor olaparib after completion of standard neoadjuvant…
PARP inhibitor shrinks tumours in pancreatic cancer patients with mutations
More than two-thirds of pancreatic cancer patients harbouring genetic mutations saw their tumour stop growing…
Study evaluates cost-effectiveness of olaparib for metastatic pancreatic cancer
Studies have shown that utilising a PARP inhibitor in the management of patients with metastatic…
Aggressive childhood cancer could be treated by combining DNA-damage targeting drugs
An aggressive form of the childhood cancer neuroblastoma could be treatable with two cancer drugs currently…